Challenges and advances for glioma therapy based on inorganic nanoparticles

Hu, Die; Miao, Xiangshui; Wu, Linquan; Liu, Hanmeng; Chen, Zhigang; Xu, Heng; He, Chuan; Wen, Jian; Xu, Xiaoqian

doi:10.1016/j.mtbio.2023.100673

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Other1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 285 publications

(316 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent progress in nanotechnology and nanomedicine holds great promise for the efficient treatment of glioma. 6,7 A range of nanoscale drug delivery systems including but not limited to inorganic nanomaterials, 8 dendrimers, 9 polymer nanoparticles (NPs), 10 liposomes, 11 micelles, 12 and nanogels 13,14 have been developed. These carriers can be used to encapsulate various kinds of therapeutic molecules and contrast agents such as small molecular drugs, proteins, peptides, genes, gold (Au) NPs, and so on, through physical or chemical interactions.…”

Section: Introductionmentioning

confidence: 99%

Blood–brain barrier-crossing dendrimers for glioma theranostics

Wang,

Zhang

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Blood–brain barrier-crossing dendrimers for glioma theranostics

Wang,

Zhang

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Biomimetic nanoparticle-driven strategies for targeted drug delivery in glioblastoma

Panchal,

Mutalik,

Manikkath

2024

J Nanopart Res

View full text Add to dashboard Cite

Glioblastoma (GBM), the most prevalent primary brain tumor in adults, remains highly challenging due to its invasive nature, limited treatment effectiveness, and short median survival durations. Standard of care includes surgery, radiation, chemotherapy, and tumor treating fields; however, there has been little improvement in survival rates. Biomimetic nanoparticles (NPs), coated with cell membranes and endogenous components, have immense potential for improving chemotherapy in GBM, by imitating cellular architecture and eluding immune clearance. With more individualized and efficient drug delivery, immunotherapeutic approaches and biomimetic NPs may increase patient survival rates. This article summarizes the main research on biomimetic NPs for GBM therapy, focusing on the classification, mechanisms, advantages, and challenges, along with the advancements in the development of GBM vaccines.

show abstract